**Supplemental Digital Content 11. Association of stunting and underweight at 6 and 12 months with duration and type of ART exposure and maternal disease progression.**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Exposures** | **Stunting at 6 month** | | **Stunting at 12 month** | | **Underweight at 6 months** | | **Underweight at 12 months** | |
| **Unadjusted OR (95%CI)** | **Adjusted OR (95%CI)** | **Unadjusted OR (95%CI)** | **Adjusted OR (95%CI)** | **Unadjusted OR (95%CI)** | **Adjusted OR (95%CI)** | **Unadjusted OR (95%CI)** | **Adjusted OR (95%CI)** |
| **Timing of ART exposure** |  |  |  |  |  |  |  |  |
| From conception | 1.12(0.65, 1.94) | 1.79(0.86, 3.75) | 1.59(0.89, 2.86) | 1.44 (0.64, 3.23) | 1.34(0.63, 2.84) | 2.08(0.84, 5.11) | 1.15(0.39, 3.41) | 1.05(0.19, 5.88) |
| From early pregnancy | 0.63(0.28, 1.40) | 0.44(0.18, 1.12) | 1.59(0.79, 3.21) | 1.83 (0.81, 4.13) | 0.32(0.07, 1.44) | 0.37(0.08, 1.73) | 0.65(0.13, 3.14) | 0.25(0.02, 3.16) |
| From late pregnancy | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| **Type of ART** |  |  |  |  |  |  |  |  |
| TDF-3TC-EFV/NVP | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| ZDV-3TC-EFV/NVP | 0.93(0.48, 1.79) | 0.58(0.14, 0.87) | 1.09(0.53, 2.27) | 0.92 (0.36, 2.37) | 0.60(0.18, 2.04) | 0.35(0.09, 1.32) | 0.89(0.20, 4.06) | 1.39(0.20, 9.54) |
| PI-based ARTs | -- | -- | -- | -- | 2.41(0.27, 21.32) | --- | --- | --- |
| **Maternal disease progression** |  |  |  |  |  |  |  |  |
| Early stage | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Advanced stage | 0.82(0.41, 1.62) | 1.16(0.47, 2.85) | 2.27(1.25, 4.13) | 1.50(0.69, 3.25) | 1.86(0.82, 4.18) | 1.86(0.68, 5.03) | 1.72(0.58, 5.12) | 2.10(0.37, 11.84) |

Each model is adjusted for maternal age, education, BMI, parity, infants’ gender, and breastfeeding status. In addition the model the for duration of ART exposure was adjusted for type of ART and maternal disease progression and vice versa.

ART: antiretroviral therapy, ZDV: Zidovudine, 3TC: lamivudine, EFV: efavirenz, NVP: nevirapine, TDF: tenofovir, PI: Protease inhibitor; OR: Odds ratio; CI: confidence interval.